Literature DB >> 1719253

The innervation of the human prostate gland--the changes associated with benign enlargement.

C R Chapple1, R Crowe, S A Gilpin, J Gosling, G Burnstock.   

Abstract

Different regions of the prostate gland, namely prostatic capsule, peripheral prostate and central prostate (subdivided into proximal (near the bladder neck), distal (near the verumontanum) and midway between these areas) were obtained from 32 obstructed (stable obstructed, n = 8; unstable obstructed, n = 13; acute retention, n = 11) and five control patients. The innervation of these tissues was studied both histochemically to localise acetylcholinesterase activity and immunohistochemically for dopamine-beta-hydroxylase, 5-hydroxytryptamine, vasoactive intestinal polypeptide, neuropeptide Y, leu- and met-enkephalin, calcitonin gene-related peptide, substance P and somatostatin. In control patients the greatest density of nerves was found in the proximal central prostate, followed by the anterior capsule and distal central prostate, with the least density in the peripheral prostate. The greatest density of nerves were acetylcholinesterase positive and immunoreactive to neuropeptide Y followed (in decreasing order) by nerves immunoreactive to: vasoactive intestinal polypeptide and dopamine beta-hydroxylase; leu-enkephalin and 5-hydroxytryptamine; calcitonin gene-related peptide; met-enkephalin; substance P; somatostatin. In addition a group of periacinar 5-hydroxytryptamine-immunoreactive cells and ganglia containing acetylcholinesterase, dopamine beta-hydroxylase and all of the peptides studied except somatostatin were identified. In the prostate gland from obstructed patients there was a significant reduction in the density of acetylcholinesterase-positive nerves (p less than 0.001) when compared with the controls. A similar trend was found for dopamine beta-hydroxylase, 5-hydroxytryptamine and all of the putative neuropeptides in most areas of the prostate, the most notable exceptions being in the peripheral prostate, with an increase in dopamine beta-hydroxylase- and leu-enkephalin-immunoreactive nerves in all three groups of obstructed patients an an increase in vasoactive intestinal polypeptide- and calcitonin gene-related peptide-immunoreactive nerves in those presenting in urinary retention. The functional significance of these findings is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1719253     DOI: 10.1016/s0022-5347(17)38203-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  The effects of SB 216469, an antagonist which discriminates between the alpha 1A-adrenoceptor and the human prostatic alpha 1-adrenoceptor.

Authors:  R Chess-Williams; C R Chapple; F Verfurth; A J Noble; C J Couldwell; M C Michel
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 2.  The link between vascular dysfunction, bladder ischemia, and aging bladder dysfunction.

Authors:  Karl-Erik Andersson; Donna B Boedtkjer; Axel Forman
Journal:  Ther Adv Urol       Date:  2016-11-04

3.  A method for correlating in vivo prostate magnetic resonance imaging and histopathology using individualized magnetic resonance-based molds.

Authors:  Vijay Shah; Thomas Pohida; Baris Turkbey; Haresh Mani; Maria Merino; Peter A Pinto; Peter Choyke; Marcelino Bernardo
Journal:  Rev Sci Instrum       Date:  2009-10       Impact factor: 1.523

4.  Anatomy of the prostatic nerves.

Authors:  G Benoit; L Merlaud; G Meduri; M Moukarzel; J Quillard; M Ledroux; F Giuliano; A Jardin
Journal:  Surg Radiol Anat       Date:  1994       Impact factor: 1.246

Review 5.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 6.  Neuroendocrine peptides in the prostate.

Authors:  P J Gkonos; A Krongrad; B A Roos
Journal:  Urol Res       Date:  1995

7.  Alpha 1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Evidence for heterogeneity of chloroethylclonidine-resistant rat renal alpha 1-adrenoceptor.

Authors:  M C Michel; R Büscher; J Kerker; H Kraneis; W Erdbrügger; O E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-10       Impact factor: 3.000

Review 8.  [Pathophysiology and therapy of benign prostatic hyperplasia].

Authors:  Natalie Sampson; Stephan Madersbacher; Peter Berger
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

9.  Observational study: daily treatment with a new compound "Tradamixina" plus serenoa repens for two months improved the lower urinary tract symptoms.

Authors:  Fabrizio Iacono; Domenico Prezioso; Ester Illiano; Antonio Ruffo; Giuseppe Romeo; Bruno Amato
Journal:  BMC Surg       Date:  2012-11-15       Impact factor: 2.102

Review 10.  The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective.

Authors:  Teow J Phua
Journal:  Medicines (Basel)       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.